Role of endothelial heparanase in delayed-type hypersensitivity
Heparanase is an endoglycosidase that cleaves heparan sulfate (HS), the main polysaccharide of the basement membrane (BM). HS is responsible for BM integrity and barrier function. Hence, enzymatic degradation of HS in the vascular subendothelial BM is a prerequisite for extravasation of immune cells...
Saved in:
Published in | Blood Vol. 107; no. 9; pp. 3609 - 3616 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Elsevier Inc
01.05.2006
The Americain Society of Hematology The American Society of Hematology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Heparanase is an endoglycosidase that cleaves heparan sulfate (HS), the main polysaccharide of the basement membrane (BM). HS is responsible for BM integrity and barrier function. Hence, enzymatic degradation of HS in the vascular subendothelial BM is a prerequisite for extravasation of immune cells and plasma components during inflammation. Here, we demonstrate a highly coordinated local heparanase induction upon elicitation of delayed-type hypersensitivity (DTH) reaction in the mouse ear. By monitoring in vivo activation of luciferase gene driven by the heparanase promoter, we demonstrate activation of heparanase transcription at an early stage of DTH. We report that heparanase is produced locally by the endothelium at the site of DTH-associated inflammation. Key DTH mediators, tumor necrosis factor-α and interferon-γ, were found to induce heparanase in cultured endothelial cells. Endothelium emerges as an essential cellular source of heparanase enzymatic activity that, in turn, allows for remodeling of the vascular BM, increased vessel permeability, and extravasation of leukocytes and plasma proteins. In vivo administration of antiheparanase siRNA or an inhibitor of heparanase enzymatic activity effectively halted DTH inflammatory response. Collectively, our results highlight the decisive role of endothelial heparanase in DTH inflammation and its potential as a promising target for anti-inflammatory drug development. |
---|---|
Bibliography: | The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734. Prepublished online as Blood First Edition Paper, December 29, 2005; DOI 10.1182/blood-2005-08-3301. Reprints: Israel Vlodavsky, Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, PO Box 9649, Haifa, 31096, Israel; e-mail: vlodavsk@cc.huji.ac.il; or Michael Elkin, Department of Oncology, Hadassah University Medical Center, POB 12000 Jerusalem 91120, Israel; e-mail: melkin@hadassah.org.il. Supported by grants from the United States Army (award no. W81XWH-04-1-0235); the Israel Cancer Association; the European Commission (Fifth Framework program, contract no. QLK3-CT-2002-02049); grant 532/02 from the Israel Science Foundation; and by United States Public Health Service Grant RO1 CA106456-01 from the National Cancer Institute, National Institutes of Health. |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2005-08-3301 |